Fig. 1: SFRs promote the resolution of airway inflammation.

a, b Mice were subjected to intranasal (i.n.) administration of papain from day 0 to day 2, as illustrated in Supplementary Fig. 1c. Representative overlaid histograms and the normalized expression levels of the SFR members on ILC2s in the lungs (a) and MLN (b) were performed using flow cytometry on the designated days. n(SLAMF1, SLAMF2, SLAMF4, SLAMF5, SLAMF7) = 3 mice per group; n(SLAMF3) = 3, 5, 5, 5 and n(SLAMF6) = 4, 3, 3, 3 mice in groups shown from left to right (a); n(SLAMF3, SLAMF5, SLAMF6, SLAMF7) = 3 mice per group; n(SLAMF2) = 6, 8, 8, 8 and n(SLAMF1 and SLAMF4) = 3, 5, 5, 5 mice in groups shown from left to right (b). c Representative H&E staining of the lung tissue from WT and SFR^−/− mice on the indicated days after papain treatment (i.n., day 0, 1 and 2). d BALF cell numbers from WT and SFR^−/− mice on the indicated days after papain treatment (i.n., day 0, 1 and 2). n(WT) = 3, 5, 5, 5 and n(SFR^−/−) = 3, 4, 4, 4 mice in groups shown from left to right. e Representative panoramic view illustrating the lungs immunostaining of eosinophils from WT and SFR^−/− mice on the indicated days after papain treatment (i.n., day 0, 1 and 2). Scale bar = 2000 µm. f The number of eosinophils in BALF and lungs from WT and SFR^−/− mice on the indicated days after papain treatment (i.n., day 0, 1 and 2). n(WT) = 3, 5, 5, 5 and n(SFR^−/−) = 3, 4, 4, 4 mice in groups shown from left to right. The number of BALF cells (g) and eosinophils (h) from mice on the indicated days after IL-33 treatment (i.n., day 0, 1 and 2). n = 3 mice per group. i The number of BALF cells and eosinophils from WT and SFR^−/− mice on day 9 after A. alternata treatment (i.n., day 0, 1 and 2). n(WT) = 3 and n(SFR^−/−) = 4 mice. The data represent at two independent experiments with similar results. All data are represented as means ± SEM, and statistical analysis was performed using a two-way ANOVA (d, f–h) or two-tailed Student’s t test (i). Please refer to Supplementary Fig. 1 for further details.